IMUC - ImmunoCellular Therapeutics, Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0430
-0.0039 (-8.32%)
At close: 3:48PM EST
Stock chart is not supported by your current browser
Previous Close0.0469
Open0.0477
Bid0.0000 x 900
Ask0.0000 x 3000
Day's Range0.0400 - 0.0477
52 Week Range0.0120 - 0.0501
Volume66,617
Avg. Volume135,010
Market Cap1.803M
Beta (3Y Monthly)1.86
PE Ratio (TTM)N/A
EPS (TTM)-0.2690
Earnings DateAug 24, 2017 - Aug 25, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • PR Newswire

    ImmunoCellular Therapeutics Announces Settlement of Derivative Action Lawsuit

    LOS ANGELES, Oct. 16, 2019 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (IMUC), today announced that pursuant to an Order of the Superior Court of California, County of Los Angeles, entered on October 3, 2019, in the matter of David Wiener, derivatively and on behalf of ImmunoCellular Therapeutics, Ltd. v. Fractor et al., Case No. BC670134, the final approval of the derivative settlement is granted and the complaint is dismissed with prejudice. With the successful conclusion of the derivative action and the recently completed sale of various company assets, ImmunoCellular plans to continue to pursue additional strategic alternatives, including a potential reverse merger with a private company seeking an expedited route to the public markets. As of September 30, 2019, ImmunoCellular's balance sheet reflected a cash position of approximately $1.9 million with no debt or other liabilities other than ongoing trade payables related to its limited operations.

  • PR Newswire

    ImmunoCellular Therapeutics Announces Completion of Asset Purchase Transaction with Private Biotechnology Company

    LOS ANGELES, Aug. 28, 2019 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (IMUC) today announced receipt of payment of $500,000 in conjunction with the completion of a transaction for the purchase of substantially all of ImmunoCellular's remaining assets, including its preclinical and clinical programs, technology, intellectual property and know-how. The first upfront payment of $500,000 was received by ImmunoCellular upon the initial closing of the asset sale transaction on May 8, 2019, and was non-refundable. The second, or continuation, payment of $500,000, which has been received, was dependent upon the satisfactory outcome of certain discussions between the Purchaser and the US Food and Drug Administration.

  • GlobeNewswire

    ImmunoCellular Therapeutics: Notice of Proposed Settlement of Derivative Action

    ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (IMUC), today issued the following announcement. ALL OWNERS OF IMMUNOCELLULAR THERAPEUTICS, LTD. (“IMMUNOCELLULAR” OR THE “COMPANY”) COMMON STOCK (TICKER SYMBOL: IMUC) AS OF JULY 24, 2019, WHO CONTINUE TO OWN SUCH SHARES (“CURRENT IMMUNOCELLULAR STOCKHOLDERS”).

  • PR Newswire

    ImmunoCellular Therapeutics Announces Asset Purchase Agreement with Private Biotechnology Company

    LOS ANGELES, July 16, 2019 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (IMUC), today announced an agreement with a privately held biotechnology company (the "Purchaser") for the purchase of substantially all of ImmunoCellular's remaining clinical and pre-clinical assets, including its preclinical and clinical programs, technology, intellectual property and know-how. ImmunoCellular's therapeutic assets are comprised of ICT-107 (phase 3-ready for glioblastoma), ICT-121 (phase 1 completed for recurrent glioblastoma) and ICT-140 (phase 1/2-ready for ovarian cancer), each of which is a patient-specific dendritic cell-based immunotherapy targeting solid tumors.